Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boehringer Ingelheim GmbH

http://www.boehringer-ingelheim.com/

Latest From Boehringer Ingelheim GmbH

Finance Watch: Lilly, Fosun Reveal Strategic Investments In Start-Ups, Growth-Stage Firms

Private Company Edition: Lilly will open a third accelerator, this time in San Diego, and Fosun partnered with Treehill to help later-stage firms get over the finish line. Also, Flagship – after recent UK investments – signals its next fund will total $3bn. ArrivoBio and Alto Neuroscience raised $45m each.

Financing Innovation

Pfizer’s Mixed Readout Places Doubt On Oral GLP-1 For Obesity

Twice-daily danuglipron reduced weight in a Phase IIb trial but with a poor side-effect profile and high discontinuation rates. Pfizer is working on a once-daily formulation it hopes will offer better tolerability.

Clinical Trials Business Strategies

Fueled By Lilly And Novo Buy-Outs, Forbion Looks To Make Most Of ‘Buyers’ Market’

Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.

Companies Financing

Drug Candidates For NASH & Epilepsy Disorder Secure EMA PRIME Designations

The developers of survodutide and elsunersen will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.

Europe Research & Development
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Abexxa Biologics Inc
    • AMAL Therapeutics SA
    • ICD Therapeutics
    • NBE Therapeutics AG
    • SSP Co., Ltd.
    • Vira Therapeutics GmbH (Vira T)
UsernamePublicRestriction

Register